Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


White Paper: New horizons to drive the future of Medicine

The European Technology Platform on Nanomedicine (ETPN) and the NANOMED2020 project announce the publication of the White Paper on Contribution of Nanomedicine to Horizon 2020, the next European Framework Programme for Research and Innovation till 2020.

This strategic document provides a set of key recommendations for the European Commission and the EU Member States to create a favourable ecosystem for the successful deployment of Nanomedicine in Europe. It lays thereby the groundwork to manage the efficient translation of nanotechnology from a Key Enabling Technology (KET) into new and innovative medical products.

Nanomedicine, also defined as the use of nanotechnologies in medicine, supports a strong research and emerging industrial healthcare sector in Europe. Based on excellent academic research and innovative SMEs, nanomedicine has the potential to answer today’s societal challenges such as the ageing population. ETPN’s White Paper will actively contribute to shaping the three pillars of “Horizon 2020 – Excellence in Science, Industrial Leadership and Societal Challenges”.

Based on an in-depth analysis of the main bottlenecks in the translation of nanomedicine to the market, i.e. the inefficient selection process of translatable projects and the lack of technical infrastructures, such as pharmacology and toxicology facilities, the White Paper strives for the creation of an strong SME based supply chain for innovative therapeutics and diagnostics as a profitable industrial sector. This will support innovation, competitiveness and keep production and high tech jobs in Europe for the benefit of both the European economy and European patients.

The pivotal proposition of the White Paper is the establishment of a Nanomedicine Translation Hub designed as an umbrella for a set of complementary actions and initiatives such as:

• a dedicated Nanomedicine Translation Advisory Board (TAB) with experienced industrial experts to select, guide and push forward the best translatable concepts,
• an European Nano-Characterisation Laboratory (EU-NCL) for physical, chemical and biological characterisation of nanomaterials intended for medical use,
• GMP manufacturing pilot lines for clinical batches to assist both academia and SMEs to develop nanomedical materials for validation in clinical trials, before transfer to dedicated manufacturing organisations,

• a dedicated NanoMed SME instrument aiming at funding discovery projects and innovative SMEs in order to keep excellence in nanomedicine research and more importantly develop products.

Nano-concepts for a macro-impact on EU economy

The implementation of these recommendations in Horizon 2020 represents a unique opportunity for Europe to foster innovation in healthcare and to push for the emergence of a leading nanomedicine sector. With an estimated total budget of 800 Mio €, it will therefore actively contribute to the re-localisation of pharmaceutical research and to the re-industrialisation of Europe, being thereby a significant factor for growth and for job creation. With nearly 250 “nano”-products used or tested in humans worldwide, representing about 10% of pharma sales and a $130.9 billion market by 2016, nanomedicine is meant to have a real impact on the European economy.

The European Commission has the potential to play a major role in this process through its framework programme Horizon 2020. In coordination with Member States and by funding the research of cutting-edge technologies for the future of Medicine, by de-risking innovation in SMEs and by facilitating the dialogue with regulatory authorities and large industrial partners, the European Commission can actively support the nanomedical sector for the benefit of the patients.

The White Paper “Contribution of Nanomedicine to Horizon 2020” is available for download on the ETP Nanomedicine website under

About the ETP Nanomedicine

The ETP Nanomedicine has been established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. With more than 120 active members from industry, academia, healthcare providers and public authorities, the ETPN coordinates joint research efforts together with its members, the European Commission and the EU Member States. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe and contributed to set up numerous EU funded projects providing thus a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicines.

About NANOMED2020

NANOMED2020 is a Coordination and Support Action under the FP7-Health aiming at delivering concrete recommendations to the European Commission to push forward the field of nanomedicine under Horizon 2020. Amongst other activities, NANOMED2020 is focusing on

• federating the nanomedicine community and establishing a European landscape via mapping all relevant actors, projects and infrastructures and

• identifying the key bottlenecks of the value chain to focus on to leverage the translational possibilities of the development process and to bring in the end more products onto the market.

This project involves seven partners across Europe including the ETPN Secretariat, the CLINAM foundation (Switzerland), the National Institute of Health Carlos III (Spain), Bioanalytik-muenster e.V (Germany), Nanobiotix SA (France), the Fondazione Don Carlo Gnocchi ONLUS (Italy), and SINTEF (Norway).

Mr. Nicolas Gouze
Head of ETP Nanomedicine Secretariat / NANOMED2020 coordinator
c/o VDI/VDE Innovation + Technik GmbH

Wiebke Ehret | idw
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

TRAPPIST-1 planets provide clues to the nature of habitable worlds

21.03.2018 | Physics and Astronomy

The search for dark matter widens

21.03.2018 | Materials Sciences

Natural enemies reduce pesticide use

21.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>